Potential Association of Favipiravir with Enhanced Ischemia/Reperfusion Injury in Rat Liver Tissue
Latin American Journal of Pharmacy, vol.43, no.10, pp.2169-2176, 2024 (Peer-Reviewed Journal)
- Publication Type: Article / Article
- Volume: 43 Issue: 10
- Publication Date: 2024
- Journal Name: Latin American Journal of Pharmacy
- Journal Indexes: LATINDEX. Catálogo v2.0 (2018 - )
- Page Numbers: pp.2169-2176
- Hacettepe University Affiliated: Yes
Abstract
The researchers used biochemical and histopathological tests to determine the effect of favipiravir on ischemia/reperfusion (I/R)-induced liver injury in rats. Eighteen male albino Wistar rats in three groups(sham,liver I/R,Favipiravir+liver I/R) underwent liver ischemia/reperfusion. Biochemical and histopathological analyses were performed. tGSH levels were greater in the SG group than in the LIR group and higher in the LIR group than in the FIR group, according to the findings. Furthermore, NF-κB, TNF-α, IL-1β, MDA, ALT, and AST levels were considerably higher in the LIR and FIR groups compared to the SG group. The FIR group had a higher proportion of necrotic/pycnotic nuclei, indicating cell death, according to histopathological analyses. The study shows that favipiravir, which is routinely used to treat COVID-19, can aggravate liver damage in diseases involving I/R injury, such as liver transplantation or major liver surgery. As a result, in such instances, the administration of favipiravir should be carefully evaluated.